Zaiqi Wang

Zaiqi Wang has served as their chairman and CEO since November 2018.Prior to this, Dr. Zaiqi Wang served as GM, Roche China Innovation Center from 2017 to Nov 2018 where he managed 140 scientists and over 10 programs from discovery to early development. From 2011 to 2017, Dr. Zaiqi Wang served as Vice President at MSD China Development Center during which time he was responsible for all China clinical programs; key driver for NDA approval of Keytruda, Gardasil, Zepatir, Rotateq, Noxafil, Emend, Orgalutran and Bridion in China and led the overall Keytruda China development strategy, especially by driving melanoma as the leading indication. From 2001 to 2010, Dr. Zaiqi Wang was served as Director of Early Clinical Research and Experimental Medicine at Schering Plough where he was responsible for 7 FIH programs, and built up the translational research unit in Singapore, Chaired VLA-4 early development program and served as chair for protocol review committee for 2 years.

Previously he was served as Assistant Clinical Pharmacologist, Phase 1 Unit at Eli Lilly from June 2001 to Dec 2001. Dr. Zaiqi Wang is Internist with board-certified Clinical Pharmacology in U.S. and he received PhD in Biochemistry from Virginia Tech and pursued his Postdoc in John Hopkins University.